Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
Saved in:
| Title: | Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. |
|---|---|
| Authors: | Strutton DR; Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL-D4555, Collegeville, PA 19426-3930, USA., Farkouh RA, Rubin JL, McGarry LJ, Loiacono PM, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC |
| Source: | BMC infectious diseases [BMC Infect Dis] 2012 Aug 03; Vol. 12, pp. 175. Date of Electronic Publication: 2012 Aug 03. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
